ReviewCancer cytopathology2019
Immunocytochemistry for predictive biomarker testing in lung cancer cytology.
Review in Cancer cytopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 114 citations in OpenAlex.
- [Diagnostics of lung diseases based on small specimens : Biopsies and cytology].Pathologie (Heidelberg, Germany) · 2026Review
- Review
- Clinicopathological Features of Non-Small Cell Lung Carcinoma with NRAS Mutation.Journal of personalized medicine · 2025Article
- Historic p87 Is Diagnostic for Lung Cancer Preceding Clinical Presentation by at Least 4 Years.Cancers · 2025Article
- Diagnostic and Predictive Immunocytochemistry in Lung Cancer.Acta cytologica · 2025Review
- Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer.Clinical and experimental medicine · 2024Review
- The Feasibility and Diagnostic Adequacy of PD-L1 Expression Analysis Using the Cytoinclusion Technique in Bladder Cancer: A Prospective Single-Center Study.Journal of clinical medicine · 2024Article
- Article
- Impact of CT-guided hookwire localization on tumor spread through air spaces in stage IA lung adenocarcinoma.Heliyon · 2024Article
- The rapidly changing field of predictive biomarkers of non-small cell lung cancer.Pathology oncology research : POR · 2024Review
- Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.Current oncology (Toronto, Ont.) · 2023Article
- Reliability of assessing morphologic features with prognostic significance in cytology specimens of epithelioid diffuse pleural mesothelioma and implications for cytopathology reporting.Cancer cytopathology · 2023Article
- Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer.Cells · 2023Article
- Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics.Pathobiology : journal of immunopathology, molecular and cellular biology · 2023Article
- Decoding SEC24 Homolog D, COPII coat complex component accuracy as a signature gene in three human cancers.American journal of cancer research · 2023Article
- Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management.Virchows Archiv : an international journal of pathology · 2022Review
- A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2022Review
- [Predictive immunocytochemistry in non-small cell lung carcinoma].Der Pathologe · 2022Review
- Stapler-lavage cytology using a new rapid immunocytochemistry for evaluating surgical margin status after pulmonary sublobar resection.General thoracic and cardiovascular surgery · 2022Article
- Novel cytological model for the identification of early oral cancer diagnostic markers: The carcinoma sequence model.Oncology letters · 2022Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 11 institutions in 7 countries.
Funding
Abstract
With an escalating number of predictive biomarkers emerging in non-small cell lung carcinoma (NSCLC), immunohistochemistry (IHC) is being used as a rapid and cost-effective tool for the screening and detection of many of these markers. In particular, robust IHC assays performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue are widely used as surrogate markers for ALK and ROS1 rearrangements and for detecting programmed death ligand 1 (PD-L1) expression in patients with advanced NSCLC; in addition, they have become essential for treatment decisions. Cytology samples represent the only source of tumor in a significant proportion of patients with inoperable NSCLC, and there is increasing demand for predictive biomarker testing on them. However, the wide variation in the types of cytology samples and their preparatory methods, the use of alcohol-based fixatives that interfere with immunochemistry results, the difficulty in procurement of cytology-specific controls, and the uncertainty regarding test validity have resulted in underutilization of cytology material for predictive immunocytochemistry (ICC), and most cytopathologists limit such testing to FFPE cell blocks (CBs). The purpose of this review is to: 1) analyze various preanalytical, analytical, and postanalytical factors influencing ICC results; 2) discuss measures for validation of ICC protocols; and 3) summarize published data on predictive ICC for ALK, ROS1, EGFR gene alterations and PD-L1 expression on lung cancer cytology. Based on our experience and from a review of the literature, we conclude that cytology specimens are in principal suitable for predictive ICC, but proper optimization and rigorous quality control for high-quality staining are essential, particularly for non-CB preparations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.